| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/05/2014 | CN101495464B Prokineticin 1 receptor antagonists |
| 03/04/2014 | US8666680 Recombinant soluble FC receptors |
| 03/04/2014 | US8664360 BSL3 polypeptides |
| 03/04/2014 | US8664247 Acyclic organonitro compounds for use in treating cancer |
| 03/04/2014 | US8664222 Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| 03/04/2014 | US8664204 Phosphoramidate alkylator prodrugs |
| 03/04/2014 | US8664182 Methods of inhibiting cancer cell growth with HDAC inhibitors and methods of screening for HDAC10 inhibitors |
| 03/04/2014 | US8663606 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 03/04/2014 | CA2675374C Formulations for parenteral administration of amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones |
| 03/04/2014 | CA2533918C Use of adcc-optimized antibodies for treating weak patients |
| 03/04/2014 | CA2444164C Pufa polyketide synthase systems and uses thereof |
| 02/27/2014 | WO2014031936A2 Heterocyclic modulators of hif activity for treatment of disease |
| 02/27/2014 | WO2014031933A2 Heterocyclic modulators of hif activity for treatment of disease |
| 02/27/2014 | WO2014031928A2 Heterocyclic modulators of hif activity for treatment of disease |
| 02/27/2014 | WO2014031901A1 Methods of use for monomethyl fumarate and prodrugs thereof |
| 02/27/2014 | WO2014031807A1 Sin3b complex inhibition and use thereof in the prevention of pro-oncogenic inflammation and cancer |
| 02/27/2014 | WO2014031755A1 Fendiline derivatives and methods of use thereof |
| 02/27/2014 | WO2014031727A1 Ferritin-based tumor targeting agent, and imaging and treatment methods |
| 02/27/2014 | WO2014031553A1 Placental vaccination therapy for cancer |
| 02/27/2014 | WO2014031487A1 Bivalent inhibitors of iap proteins and therapeutic methods using the same |
| 02/27/2014 | WO2014031204A2 Carbohydrate-selective receptors |
| 02/27/2014 | WO2014031012A1 Novel prodrugs and methods of use thereof |
| 02/27/2014 | WO2014030972A1 Anticancer composition |
| 02/27/2014 | WO2014030763A1 Anti-tumor agent |
| 02/27/2014 | WO2014030602A1 Agent for treating cancer |
| 02/27/2014 | WO2014030597A1 Novel compound and method for producing same, novel microorganism, pharmaceutical composition, and anti-tumor agent |
| 02/27/2014 | WO2014030250A1 Antitumor agent |
| 02/27/2014 | WO2014030001A1 Fused heterocyclic compounds and their use |
| 02/27/2014 | WO2014029888A2 Branched or macrocyclic polyamines and uses thereof |
| 02/27/2014 | WO2014029732A1 Pyrrolo[2,3-b]pyrazines as syk inhibitors |
| 02/27/2014 | WO2014029726A1 Novel phenyl-pyridine/pyrazine amides for the treatment of cancer |
| 02/27/2014 | WO2014029669A1 Combinations (catechins and methotrexate) for use in the treatment of melanomas |
| 02/27/2014 | WO2014029250A1 Benazepine compound and application thereof |
| 02/27/2014 | WO2014029022A1 Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
| 02/27/2014 | WO2014029016A1 Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer |
| 02/27/2014 | WO2014011900A3 Inhibitors of the fibroblast growth factor receptor |
| 02/27/2014 | WO2014008206A3 DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E |
| 02/27/2014 | WO2014008204A3 Structures of proteasome inhibitors and methods for synthesizing and use thereof |
| 02/27/2014 | WO2013192556A3 Salt crystals |
| 02/27/2014 | WO2013192144A3 Rift valley fever virus replicon particles |
| 02/27/2014 | WO2013190137A3 Novel anti-cancer thiophene compounds |
| 02/27/2014 | WO2013188783A8 Deuterated derivatives of ruxolitinib |
| 02/27/2014 | WO2013013302A8 Synthetic lethality and the treatment of cancer |
| 02/27/2014 | US20140057995 Aqueous-lipidic carotenoid-containing compositions |
| 02/27/2014 | US20140057898 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 02/27/2014 | US20140057897 Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias |
| 02/27/2014 | US20140057863 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| 02/27/2014 | US20140056974 Spontaneously Dispersible N-Benzoyl Staurosporine Compositions |
| 02/27/2014 | US20140056921 Hepatocyte Growth Factor Receptor Antagonists and Uses Thereof |
| 02/27/2014 | US20140056887 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| 02/27/2014 | CA2876543A1 Pyrrolo[2,3-b]pyrazines as syk inhibitors |
| 02/26/2014 | EP2700652A1 Diagnosis and treatment of cancer using anti-itm2a antibody |
| 02/26/2014 | EP2700642A1 Camptothecin compound containing stable 7-membered lactone ring, preparation method and use |
| 02/26/2014 | EP2700638A1 Purine analogs |
| 02/26/2014 | EP2700404A1 Antcin derivatives in combination with an anti-cancer drug in treatment and/or prevention of tumors |
| 02/26/2014 | EP2700403A1 Therapeutic agent for tumor |
| 02/26/2014 | EP2699602A2 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
| 02/26/2014 | EP2699599A2 Gpr177 as target and marker in tumors |
| 02/26/2014 | EP2699598A2 Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| 02/26/2014 | EP2699592A2 Anticancer fusion protein |
| 02/26/2014 | EP2699575A1 Triazolopyridines |
| 02/26/2014 | EP2699574A1 Bicyclic heterocycle compounds and their uses in therapy |
| 02/26/2014 | EP2699573A2 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1h-imidazo[4,5-c]quinoline derivatives |
| 02/26/2014 | EP2699572A1 Heterocyclic compounds as kinase inhibitors |
| 02/26/2014 | EP2699568A1 A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| 02/26/2014 | EP2699567A1 Insulin-like growth factor-1 receptor inhibitors |
| 02/26/2014 | EP2699564A1 Substituted pyrimidinyl-pyrroles active as kinase inhibitors |
| 02/26/2014 | EP2699561A1 Androgen receptor modulating carboxamides |
| 02/26/2014 | EP2699554A1 Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines |
| 02/26/2014 | EP2699551A1 Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| 02/26/2014 | EP2699550A1 Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| 02/26/2014 | EP2699319A1 Niclosamide for the treatment of cancer metastasis |
| 02/26/2014 | EP2699273A2 Radioactive solutions for treating cancer |
| 02/26/2014 | EP2699268A2 Novel binder-drug conjugates (adcs) and their use |
| 02/26/2014 | EP2699262A2 Bispecific antibodies against her2 and cd3 |
| 02/26/2014 | EP2699260A1 Bispecifc antibodies against her2 |
| 02/26/2014 | EP2699240A2 Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same |
| 02/26/2014 | EP2699237A2 Therapy for leukemia |
| 02/26/2014 | EP2699233A1 A method for the treatment of a solid tumour |
| 02/26/2014 | CN103608350A Triazolopyridine compounds |
| 02/26/2014 | CN103608342A Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids |
| 02/26/2014 | CN103608333A 雄激素受体拮抗剂及其用途 Androgen receptor antagonists and their use |
| 02/26/2014 | CN103608043A Alpha-emitting complexes |
| 02/26/2014 | CN103608037A Use of anti-DKK1 monoclonal antibody for treatment of liver cancer |
| 02/26/2014 | CN103608033A Individualized vaccines for cancer |
| 02/26/2014 | CN103608029A Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) |
| 02/26/2014 | CN103608028A Human myeloid derived suppressor cell cancer markers |
| 02/26/2014 | CN103608026A Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion |
| 02/26/2014 | CN103608019A Anti-tumor agent |
| 02/26/2014 | CN103608018A Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines |
| 02/26/2014 | CN103608006A New combination comprising N-acetyl-L-cysteine and its use |
| 02/26/2014 | CN103602724A Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells |
| 02/26/2014 | CN103602706A MUC1 (Mucins 1) and GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) dual-gene co-expression recombinant vector and preparation method and application thereof |
| 02/26/2014 | CN103602695A GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) and MART-1 (Melanoma Antigen Recognized By T-Cells 1) dual-gene co-expression recombinant vector and preparation method and application thereof |
| 02/26/2014 | CN103602634A Preparation method of DCs, and application of DCs in preparing anti-tumor cell preparation |
| 02/26/2014 | CN103602625A Escherichia coli containing recombinant adenovirus plasmids and applications of recombinant adenovirus plasmids |
| 02/26/2014 | CN103601806A Il-6结合分子 Il-6 binding molecules |
| 02/26/2014 | CN103601792A Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| 02/26/2014 | CN103601762A Ferrocene derivatives, preparation method and use thereof |
| 02/26/2014 | CN103601742A Largazole analogue, and preparation method and applications thereof |